Pharmaceutical Executive
Pharmaceutical Executive
Pharmaceutical Executive Podcast
Pharmaceutical Executive Daily: FDA Requires Safety Label Update on GLP-1 Receptor Agonist
2 minutes Posted Nov 10, 2026 at 5:00 pm.
0:00
2:27
Download MP3
Show notes
FDA approves Bayer’s asundexian as the first Factor XIa inhibitor for secondary stroke prevention, the FDA requires a new safety label warning across all GLP-1 receptor agonists for a potential NAION risk, and AstraZeneca acquires Omniose to add a bioconjugation platform to its vaccine pipeline.